{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:20:50Z","timestamp":1769505650763,"version":"3.49.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jdin.2025.02.001","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T16:56:59Z","timestamp":1742317019000},"page":"54-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis"],"prefix":"10.1016","volume":"20","author":[{"given":"Nikki","family":"Zangenah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Vazquez-Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Loranger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soha","family":"Elshaboury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avery H.","family":"LaChance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jdin.2025.02.001_bib1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus Adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jdin.2025.02.001_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jdin.2025.02.001_bib3","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jaad.2020.05.105","article-title":"Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study","volume":"83","author":"Blauvelt","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2025.02.001_bib4","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaad.2024.05.085","article-title":"Real-world experience of bimekizumab for adult patients with plaque psoriasis: a 52-week multicenter retrospective study","volume":"91","author":"Sood","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2025.02.001_bib5","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1002\/ski2.418","article-title":"Bimekizumab as treatment for moderate to severe chronic plaque psoriasis: real world clinical experience from a district general hospital setting","volume":"4","author":"Ashaolu","year":"2024","journal-title":"Skin Health Dis"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328725000239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328725000239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:58:18Z","timestamp":1747187898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328725000239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":5,"alternative-id":["S2666328725000239"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2025.02.001","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2025.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}